Khaled Musallam on Management of Transfusion-Dependent β-Thalassaemia in LMICs
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”On the first day of 2026, I’m delighted to share one of my favourite pieces of work—published today in The Lancet Haematology and featured on the cover.
This Viewpoint introduces a practical decision matrix to help prioritise novel therapies for thalassemia—including disease-modifying and gene therapies—based on need, benefit, and risk, particularly in settings where access remains limited.
It also proposes realistic alternatives when standard options are not available.
The work builds on Thalassaemia International Federation guidelines, the best available trial and real-world evidence, and expert consensus from a truly global group of haematologists, transplant physicians, patient representatives, translational scientists, and trialists—bringing together 200+ years of collective clinical experience across Asia, the Middle East, Europe, and North America.
Grateful to an exceptional group of co-authors and hopeful this framework helps support more equitable, evidence-based care for patients worldwide.”
Read the full article in The Lancet Hematology.
Article: Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources
Authors: Khaled Musallam, Sujit Sheth, Maria Domenica Cappellini, Farrukh Shah, Stefano Rivella, Vijay G Sankaran et al.
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 3, 2026, 16:57Ahmed Alotaibi: Which Macrophage Receptor ‘eats’ anti-E and Anti-K Coated RBCs?
-
Nov 3, 2026, 16:53Jan Sloves: Key Factors for Achieving Durable Patency in Advanced Venous Stenting
-
Nov 3, 2026, 16:45Nina Weber: Review on Kidney Injury After Stem Cell Transplantation
-
Nov 3, 2026, 16:36Chris Baugh: EMplify Podcast Explores Antithrombotic Associated Bleeding in the Emergency Department
-
Nov 3, 2026, 16:32Carlo Zaninetti: Highlights from the XXIX Congress of the Italian Society on Haemostasis and Thrombosis
-
Nov 3, 2026, 15:10Lady Joan Branson’s Story – The Hidden Danger of Hospitalization
-
Nov 3, 2026, 14:38Emna Hammami: Exploring the Haemophilia Treatment Landscape at the EHC New Technologies Conference
-
Nov 3, 2026, 14:20EHC Marks the Final Edition of Its New Technologies Conference in Bucharest
-
Nov 3, 2026, 14:15Rhiannon Morris: Awarded CASS Foundation Travel Grant to Present Research at ASH 2026